Folster
ASFN Icon
- Joined
- Jun 23, 2005
- Posts
- 16,830
- Reaction score
- 7,341
I took a look at GSK the other day. The first thing that struck me was a significant drop in revenue that was forecasted for 2022. Analysts are projecting $33B down from $46.6B in 2021. That made me think they sold off a chunk of their business and sure enough they spun-off their consumer healthcare biz now called Haleon (HLN) which I read PFE also spun their consumer healthcare segment into as well. I'm not sure of the specifics, but both firms want to concentrate on developing pharmaceuticals and therapeutics. JNJ also recently made plans to spin off their consumer healthcare and so is 3M so this is an obvious trend in the industry.
Spinning off their consumer staples business could increase margins and multiples, but also cause more volatility in revenue and earnings.
They have quite a bit of debt, but seem to be able to carry it based on the common debt ratios. The dividend yield is also inflated now and will be reduced after the spin-off. It looks like they are targeting 40-60% of net income which will probably be a yield of 4-5%.
Anyway, after their decrease in revenue, I projected annual growth of about 6% a year for the next 5 years using analyst estimates. When I discount the projected cash flows back 5 years with my required return of 10%, I get a target share price of just under $30 after accounting for their debt.
Obviously there are a lot of variables and unknowns with the spin-off, but it seems pretty fairly priced right now, but not a screaming deal. I read that they expect increases in their operating margins so if that can flow through to the bottom line, they could see richer valuations in the future.
Spinning off their consumer staples business could increase margins and multiples, but also cause more volatility in revenue and earnings.
They have quite a bit of debt, but seem to be able to carry it based on the common debt ratios. The dividend yield is also inflated now and will be reduced after the spin-off. It looks like they are targeting 40-60% of net income which will probably be a yield of 4-5%.
Anyway, after their decrease in revenue, I projected annual growth of about 6% a year for the next 5 years using analyst estimates. When I discount the projected cash flows back 5 years with my required return of 10%, I get a target share price of just under $30 after accounting for their debt.
Obviously there are a lot of variables and unknowns with the spin-off, but it seems pretty fairly priced right now, but not a screaming deal. I read that they expect increases in their operating margins so if that can flow through to the bottom line, they could see richer valuations in the future.